Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Focused execution across multiple revenue channels with Lifeline providing the quickest path to near-term profitability and Cle...
Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and raises the price target from $9 to $9.5.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arra...
Surgepays (NASDAQ:SURG) sees FY2025 sales of $75.000 million-$90.000 million vs $94.162 million analyst estimate.
Surgepays (NASDAQ:SURG) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.20) b...
